Cancer Vaccines in the Checkpoint Era: Neoantigens, mRNA, and Phase 3 Progress
Cancer vaccines have been pursued for decades, yet repeated late-stage disappointments led many to doubt whether therapeutic vaccination could ever deliver meaningful clinical benefit. Those disappointments were not only about antigen choice, they were also about immune context: many early...
